Mirati Therapeutics (MRTX) PT Lowered to $130 at BMO Capital
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman lowered the price target on Mirati Therapeutics (NASDAQ: MRTX) to $130.00 (from $187.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
